List of Figures

Figure 1: Types of Acute Kidney Injury
Figure 2: Risk factors associated with Acute Kidney Injury
Figure 3: Common Causes of Acute Kidney Injury
Figure 4: Pathophysiology of Acute Kidney Injury
Figure 5: Biomarkers of Acute Kidney Injury
Figure 6: Stage-based management of Acute Kidney Injury
Figure 7: Total Incident Population of AKI in Hospitalized Patients in the 7MM (2019–2032)
Figure 8: Mortality Adjusted Incident Population of AKI in Hospitalized Patients in the 7MM (2019–2032)
Figure 9: Total Incident Population of AKI in Hospitalized Patients in the US (2019–2032)
Figure 10: Mortality Adjusted Incident Population of AKI in Hospitalized Patients in the US (2019–2032)
Figure 11: Stage-specific Incident Population of AKI in the US (2019–2032)
Figure 12: Age-specific Incident Population of AKI in the US (2019–2032)
Figure 13: Total Incident Population of AKI in Hospitalized Patients in the EU-5 (2019–2032)
Figure 14: Mortality Adjusted Incident Population of AKI in Hospitalized Patients in the EU-5 (2019–2032)
Figure 15: Stage-specific Incident Population of AKI the EU-5 (2019–2032)
Figure 16: Age-specific Incident Population of AKI in the EU-5 (2019–2032)
Figure 17: Total Incident Population of AKI in Hospitalized Patients in Japan (2019–2032)
Figure 18: Mortality Adjusted Incident Population of AKI in Hospitalized Patients in Japan (2019–2032)
Figure 19: Stage-specific Incident Population of AKI in Japan (2019–2032)
Figure 20: Age-specific Incident Population of AKI in Japan (2019–2032)
Figure 21: Market Size of AKI in the 7MM in USD million (2019–2032)
Figure 22: Market Size of AKI by Therapies in the 7MM, in USD million (2019–2032)
Figure 23: Market Size of AKI in the US, USD million (2019–2032)
Figure 24: Market Size of AKI by therapies in the US, in USD million (2019–2032)
Figure 25: Market Size of AKI in the EU-5, USD million (2019–2032)
Figure 26: Market Size of AKI by Therapies in the EU-5, in USD million (2019–2032)
Figure 27: Market Size of AKI in Japan, USD million (2019–2032)
Figure 28: Market Size of AKI by Therapies in Japan, in USD million (2019–2032)

List of Tables

Table 1: Summary of Acute Kidney Injury Market, and Epidemiology (2019–2032)
Table 2: Key Events
Table 3: Risk, Injury, Failure, Loss, and End-stage Kidney (RIFLE) classification
Table 4: KDIGO Criteria
Table 5: Causes of AKI: Exposures and Susceptibilities for non-specific AKI
Table 6: Biomarkers of AKI
Table 7: RIFLE Criteria for ARF
Table 8: AKIN Criteria for ARF
Table 9: KDIGO Criteria for AKI
Table 10: Renal Replacement Therapy (RRT) Modalities for ARF
Table 11: Total Incident Population of AKI in Hospitalized Patients in the 7MM, in Thousands (2019–2032)
Table 12:Mortality Adjusted Incident Population of AKI in Hospitalized Patients in the 7MM, in Thousands (2019–2032)
Table 13: Total Incident Population of AKI in Hospitalized Patients in the US, in Thousands (2019–2032)
Table 14: Mortality Adjusted Incident Population of AKI in Hospitalized Patients in the US, in Thousands (2019–2032)
Table 15: Stage-specific Incident Population of AKI in the US, in Thousand (2019–2032)
Table 16: Age-specific Incident Population of AKI in the US, in Thousands (2019–2032)
Table 17: Total Incidence of AKI in Hospitalized Patients in the EU-5 in Thousands (2019–2032)
Table 18: Mortality Adjusted Incident Population of AKI in Hospitalized Patients in the EU-5, in Thousands (2019–2032)
Table 19: Stage-specific Incident Population of AKI in the EU-5, in Thousands (2019–2032)
Table 20: Age-specific Incident Population of AKI in the EU-5, in Thousands (2019–2032)
Table 21: Total Incident Population of AKI in Hospitalized Patients in Japan, in Thousand (2019–2032)
Table 22: Mortality Adjusted Incident Population of AKI in Hospitalized Patients in Japan, in Thousands (2019–2032)
Table 23: Stage-specific Incident Population of AKI in Hospitalized Patients in Japan, in Thousands (2019–2032)
Table 24: Age-specific Incident Population of AKI in Japan, in Thousands (2019–2032)
Table 25: Organizations contributing toward Acute Kidney Injury (AKI)
Table 26: Comparison of emerging drugs for AKI
Table 27: SB-101, Clinical Trial Description, 2022
Table 28: RMC-035, Clinical Trial Description, 2022
Table 29: OCE-205 Clinical Trial Description, 2022
Table 30: RBT-1 Clinical Trial Description, 2022
Table 31: recAP, Clinical Trial Description, 2022
Table 32: bRESCAP, Clinical Trial Description, 2022
Table 33: EA-230, Clinical Trial Description, 2022
Table 34: Key Market Forecast Assumptions for recAP
Table 35: Key Market Forecast Assumptions for RMC--035
Table 36: Key Market Forecast Assumptions for bRESCAP
Table 37: Key Market Forecast Assumptions for EA-230
Table 38: Key Market Forecast Assumptions for RBT-1
Table 39: Key Market Forecast Assumptions for OCE-205
Table 40: Market Size of AKI in the 7MM in USD million (2019–2032)
Table 41: Market Size of AKI by therapies in the 7MM, in USD million (2019–2032)
Table 42: Market Size of AKI in the US, USD million (2019–2032)
Table 43: Market Size of AKI by therapies in the US, in USD million (2019–2032)
Table 44: Market Size of AKI in the EU-5, in USD million (2019–2032)
Table 45: Market Size of AKI by therapies in EU5, in USD million (2019–2032)
Table 46: Market Size of AKI in Japan, in USD million (2019–2032)
Table 47: Market Size of AKI by therapies in Japan, in USD million (2019–2032)